http://lookfordiagnosis.com
English
Spanish
Italian
Portuguese
French
Swedish
Dicerna Presents Preclinical Data on Primary Hyperoxaluria Type 1 Drug
Dicerna Presents Preclinical Data on Primary Hyperoxaluria Type 1 Drug. July 03, 2014. Type size: - +; Email · Printer-friendly version · RSS Feed. Full-text access for premium subscribers only. Get immediate access with a three-month trial for $95.
GenomeWeb - Tue, 01 Jul 2014 11:31

Dicerna DCR-PH1 Candidate Holds Promise for Treatment of Primary ...
The research was presented at the 11th International Primary Hyperoxaluria Workshop in Chicago by Eduardo Salido, Ph.D., Professor of Pathology at the University of La Laguna in Santa Cruz de Tenerife, Spain. The preclinical studies showed that ...
AZoNano.com - Tue, 01 Jul 2014 03:52

Sector Update: Healthcare Narrowly Lower This Afternoon; Dicerna ...
NASDAQ - Mon, 30 Jun 2014 09:52

The Latest Discovery by Dicerna Pharmaceuticals (NASDAQ:DRNA)
Stocks.org - Tue, 01 Jul 2014 20:33

Why Dicerna Pharmaceuticals Inc Stock Skyrocketed
Motley Fool - Mon, 30 Jun 2014 14:01

Dicerna Pharma (DRNA) Says Data Shows DCR-PH1 Has Promise in PH1
StreetInsider.com (subscription) - Mon, 30 Jun 2014 05:00



Love beyond borders: Pakistani boy gets 'new life' in India
Primary hyperoxaluria is a rare condition characterised by the overproduction of a substance called oxalate (also called oxalic acid). In the kidneys, the excess oxalate combines with calcium to form calcium oxalate, a hard compound that is the main ...
Daijiworld.com - Wed, 25 Jun 2014 03:14

Noida doctors give Pakistan boy a new lease of life
Times of India - Tue, 24 Jun 2014 12:41

Pakistani boy undergoes kidney, liver transplant in Noida
TheHealthSite - Wed, 25 Jun 2014 00:07



Pre-Open Stock Movers 6/30: (MNKD) (DRNA) (BK) Higher; (APP) (MBI) (WLT ...
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) 8.4% HIGHER; announced the presentation of preclinical data demonstrating the promise of DCR-PH1, the Companys therapeutic candidate for the treatment of primary hyperoxaluria type 1 (PH1), a rare ...
StreetInsider.com (subscription) - Mon, 30 Jun 2014 06:41

S&P 500 Posts Best Q2 Since 2009
(+) DRNA, Announces positive preclinical data for its DCR-PH1 drug candidate to treat primary hyperoxaluria type 1, a rare, inherited liver disorder causing progressive kidney damage. (+) MILL, Raised to Buy from Neutral at SunTrust Robinson Humphrey, ...
Investing.com - Mon, 30 Jun 2014 13:37

Don't get emotional about your investments
(+) DRNA, Announces positive preclinical data for its DCR-PH1 drug candidate to treat primary hyperoxaluria type 1, a rare, inherited liver disorder causing progressive kidney damage. (-) RMD, Cautious mention this weekend in Barron's, which writes the ...
NASDAQ - Mon, 30 Jun 2014 12:52

3 Stocks Under Wall Street's Radar: MannKind Corporation (NASDAQ:MNKD ...
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) jumped 19.80% after the presentation of preclinical data demonstrating the promise of DCR-PH1, the Company's therapeutic candidate for the treatment of primary hyperoxaluria type 1 (PH1), at the 11th ...
Markets Emerging - Tue, 01 Jul 2014 03:17

Study Updates, Market Activity, Preclinical Data, and Oral Presentations ...
... presentation of preclinical data demonstrating the promise of DCR-PH1, the Company's therapeutic candidate for the treatment of primary hyperoxaluria type 1 (PH1) - a rare inherited liver disorder that often results in progressive and severe kidney ...
MarketWatch - Thu, 03 Jul 2014 03:30


1  2  3  4    ->

Last update: April 2009
Statistics